Skip to content

Clinical study on the rapid recovery effect of Yikou Sizi powder fomentationon gastrointestinal motility after laparoscopic liver cancer surgery

Clinical study on the rapid recovery effect of Yikou Sizi powder fomentationon gastrointestinal motility after laparoscopic liver cancer surgery

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300075043
Enrollment
Unknown
Registered
2023-08-23
Start date
2023-08-15
Completion date
Unknown
Last updated
2023-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary liver cancer

Interventions

Control group
:Control group: Perioperative management was conducted in accordance with the Chinese Accelerated Rehabilitation Surgery Clinical Practice Guidelines (2021 version)
Test group:Experimental group: On the basis of the control group, apply Yiyi Sizi San traditional Chinese medicine "Re Yan Bao" hot compress to the abdomen

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 75 Years

Inclusion criteria

Inclusion criteria: ? Age range from 25 to 75 years old, regardless of gender, race, or nationality, ? ICG - R15 = 10%, ? Patients who can be clinically diagnosed as primary liver cancer through pathology, imaging and laboratory examination, and whose stage is from CNLC Ia to CNLC IIIa, and who have undergone laparoscopic Hepatectomy, ? Accepting this study, signing an informed consent form, and being able to cooperate in completing the research.

Exclusion criteria

Exclusion criteria: ? Visible other organ tumors and tumors with metastasis to other organs, ? Individuals with severe mental illness or cognitive impairment, ? Poor compliance and inability to cooperate in completing the experiment.

Design outcomes

Primary

MeasureTime frame
Time of first postoperative exhaust and defecation;postoperative gastric electrical rhythm;

Secondary

MeasureTime frame
Inflammatory factor indicators (interleukin IL-6, tumor necrosis factor TNF)- a);Gastrointestinal Symptom Rating Scale;Safety indicator;incidence of adverse reactions;

Countries

China

Contacts

Public ContactJunming He

Guangdong Provincial Hospital of Traditional Chinese Medicine

hejunming0101@sina.com+86 135 0153 8271

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026